PL375697A1 - Pirazolipirymidyny jako inhibitory kinazy zależnej od cykliny - Google Patents

Pirazolipirymidyny jako inhibitory kinazy zależnej od cykliny

Info

Publication number
PL375697A1
PL375697A1 PL03375697A PL37569703A PL375697A1 PL 375697 A1 PL375697 A1 PL 375697A1 PL 03375697 A PL03375697 A PL 03375697A PL 37569703 A PL37569703 A PL 37569703A PL 375697 A1 PL375697 A1 PL 375697A1
Authority
PL
Poland
Prior art keywords
compounds
cyclin
pyrazolopyrimidines
kinase inhibitors
dependent kinase
Prior art date
Application number
PL03375697A
Other languages
English (en)
Other versions
PL224879B1 (pl
Inventor
Timothy J. Guzi
Kamil Paruch
Michael P. Dwyer
Ronald J. Doll
Viyyoor Moopil Girijavallabhan
Alan Mallams
Carmen S. Alvarez
Kartik M. Keertikar
Jocelyn Rivera
Tin-Yau Chan
Vincent Madison
Thierry O. Fischmann
Lawrence W. Dillard
Vinh D. Tran
Zhen Min He
Ray Anthony James
Haengsoon Park
Vidyadhar M. Paradkar
Douglas Walsh Hobbs
Original Assignee
Schering Corporation
Pharmacopeia Drug Discovery, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation, Pharmacopeia Drug Discovery, Inc. filed Critical Schering Corporation
Publication of PL375697A1 publication Critical patent/PL375697A1/pl
Publication of PL224879B1 publication Critical patent/PL224879B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

W wielu wykonaniach niniejszy wynalazek dostarcza nowej klasy pirazolo[1,5-a]pirymidynowych związków jako inhibitorów zależnych od cykliny kinaz, sposobów wytwarzania takich związków, farmaceutycznych kompozycji zawierających jeden lub więcej taki związek, sposobów wytwarzania farmaceutycznych preparatów zawierających jeden lub więcej taki związek i sposobów leczenia, zapobiegania, hamowania lub łagodzenia jednej lub więcej chorób związanych z CDK z użyciem takich związków albo farmaceutycznych kompozycji.
PL375697A 2002-09-04 2003-09-03 Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja PL224879B1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40802702P 2002-09-04 2002-09-04
US60/408,027 2002-09-04
US42195902P 2002-10-29 2002-10-29
US60/421,959 2002-10-29

Publications (2)

Publication Number Publication Date
PL375697A1 true PL375697A1 (pl) 2005-12-12
PL224879B1 PL224879B1 (pl) 2017-02-28

Family

ID=31981560

Family Applications (1)

Application Number Title Priority Date Filing Date
PL375697A PL224879B1 (pl) 2002-09-04 2003-09-03 Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja

Country Status (12)

Country Link
EP (1) EP2194058B1 (pl)
JP (1) JP2010180234A (pl)
AR (1) AR041137A1 (pl)
CY (1) CY1110666T1 (pl)
DE (1) DE60332846D1 (pl)
EC (2) ECSP055642A (pl)
ES (1) ES2346204T3 (pl)
MY (1) MY138201A (pl)
PL (1) PL224879B1 (pl)
PT (1) PT1537116E (pl)
RU (1) RU2380369C9 (pl)
TW (1) TWI344468B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6007417B2 (ja) * 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
JP6573604B2 (ja) 2013-06-11 2019-09-11 セルジーン インターナショナル ツー エスエーアールエル 新規なｇｌｐ−１レセプターモジュレーター
CA2969944A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
CN116570594A (zh) 2016-06-23 2023-08-11 马里兰大学巴尔的摩分校 选择性p38α特异性MAPK抑制剂
JP7594787B2 (ja) 2018-12-07 2024-12-05 ユニバーシティ オブ メリーランド、ボルチモア 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤
CN116406355B (zh) 2020-05-18 2026-05-15 Gen1E生命科学公司 P38α促分裂原活化蛋白激酶抑制剂
AU2021370893B2 (en) 2020-10-29 2024-03-07 Gen1E Lifesciences Inc. Crystalline 5-(dimethylamino) -n- (4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate
NZ804686A (en) 2021-03-23 2026-03-27 Gen1E Lifesciences Inc Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
CN116983313B (zh) * 2023-07-13 2026-01-27 四川大学 Nu6300的新用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907799A (en) 1971-08-16 1975-09-23 Icn Pharmaceuticals Xanthine oxidase inhibitors
WO1991018904A1 (en) 1990-05-30 1991-12-12 American Home Products Corporation Substituted arylsulfonamides and benzamides
DE69130683T2 (de) 1991-04-22 1999-05-06 Otsuka Pharmaceutical Factory, Inc., Naruto, Tokushima PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0628559B1 (en) * 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
EP0714898B1 (en) 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1043998B1 (en) * 1997-12-13 2007-03-07 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE69912379T2 (de) 1998-08-14 2004-05-06 Pfizer Inc. Antithrombosemittel
WO2000026210A1 (en) 1998-10-30 2000-05-11 Merck & Co., Inc. Thrombin inhibitors
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
ATE250053T1 (de) 1999-07-15 2003-10-15 Pharmacopeia Inc Bradikinin b1 rezeptor antagonisten
WO2002010162A1 (en) 2000-07-26 2002-02-07 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
DE60122176T2 (de) 2000-09-15 2007-07-05 Vertex Pharmaceuticals Inc., Cambridge Isoxazole und ihre verwendung als erk-inhibitoren
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
JP2004516297A (ja) * 2000-12-20 2004-06-03 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） サイクリン依存性キナーゼ（ｃｄｋ）及びグリコーゲンシンターゼキナーゼ−３（ｇｓｋ−３）の阻害剤
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors

Also Published As

Publication number Publication date
JP2010180234A (ja) 2010-08-19
PL224879B1 (pl) 2017-02-28
PT1537116E (pt) 2010-09-03
ES2346204T3 (es) 2010-10-13
TW200410973A (en) 2004-07-01
EP2194058A1 (en) 2010-06-09
AR041137A1 (es) 2005-05-04
RU2005109543A (ru) 2006-05-10
ECSP055642A (es) 2005-05-30
EP2194058B1 (en) 2013-11-27
CY1110666T1 (el) 2015-06-11
RU2380369C2 (ru) 2010-01-27
MY138201A (en) 2009-05-29
ECSP11005642A (es) 2011-10-31
DE60332846D1 (de) 2010-07-15
TWI344468B (en) 2011-07-01
RU2380369C9 (ru) 2011-07-10

Similar Documents

Publication Publication Date Title
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
NO20051647L (no) Pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200420564A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
MY133311A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
MY162134A (en) Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
ATE470668T1 (de) Pyrazolopyrimidine als inhibitoren von cyclinabhängiger kinase zur behandlung von krebs
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
GB0226583D0 (en) Compounds
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
WO2007058873A3 (en) Imidazopyrazines as cyclin depentend kinase inhibitors
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
AU2003228770A8 (en) Substituted pyrazolopyrimidines